Opinion

Video

PERSEUS Trial Findings at EHA 2024

Joseph Mikhael, MD, discusses the PERSEUS trial findings presented at EHA 2024.

Video content above is prompted by the following:

  • Discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on minimal residual disease (MRD) in the PERSEUS trial of daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) induction/consolidation followed by daratumumab/lenalidomide (D-R) in patients with newly diagnosed multiple myeloma.
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
  • Please provide your key takeaways from this study. How might these findings impact the management of patients with multiple myeloma?
  • How have the criteria for multiple myeloma patients to be considered transplant-eligible or -ineligible evolved in recent history? How do you evaluate transplant eligibility in your practice?
Related Videos
This series features 1 kol.
1 KOL is featured in this series.
1 KOL is featured in this series.
This series features 1 kol.
1 KOL is featured in this series.
1 KOL is featured in this series.
This series features 1 kol.
Related Content

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo